Michael S. Rosol
2021
In 2021, Michael S. Rosol earned a total compensation of $469.4K as Chief Medical Officer Principal Executive Officer at Navidea Biopharmaceuticals, a 56% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $63,057 |
|---|---|
| Option Awards | $133,037 |
| Salary | $263,526 |
| Other | $9,731 |
| Total | $469,351 |
Rosol received $263.5K in salary, accounting for 56% of the total pay in 2021.
Rosol also received $63.1K in non-equity incentive plan, $133K in option awards and $9.7K in other compensation.
Rankings
In 2021, Michael S. Rosol's compensation ranked 10,851st out of 12,415 executives tracked by ExecPay. In other words, Rosol earned more than 12.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,851 out of 12,415 | 13th |
Division Manufacturing | 4,782 out of 5,505 | 13th |
Major group Chemicals And Allied Products | 2,145 out of 2,375 | 10th |
Industry group Drugs | 1,907 out of 2,096 | 9th |
Industry In Vitro and In Vivo Diagnostic Substances | 51 out of 61 | 16th |
Source: SEC filing on October 24, 2022.
Rosol's colleagues
We found four more compensation records of executives who worked with Michael S. Rosol at Navidea Biopharmaceuticals in 2021.
2021
Jed Latkin
Navidea Biopharmaceuticals
Chief Executive Officer
2021
Erika Eves
Navidea Biopharmaceuticals
Vice President, Finance & Administration
2021
Michel Mikhail
Navidea Biopharmaceuticals
Chief Regulatory Officer
2021
Joel Kaufman
Navidea Biopharmaceuticals
Former Chief Business Officer
News
Navidea Biopharmaceuticals Chief Medical Officer Michael Rosol's 2022 pay slips 8% to $430K
October 5, 2023
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019